For an atypical meningioma WHO grade 2 s/p GTR, do molecular findings that suggest an integrated diagnosis of a grade 3 tumor change adjuvant radiation treatment recommendations?  

Molecular findings that indicate a more aggressive WHO grade 2 meningioma would certainly support recommendations for adjuvant RT after GTR, but if these tumors have a prognosis similar to grade 3, then should the RT dose and/or treatment volumes follow guidelines for a WHO grade 3 tumor (ie higher dose, bigger margins) or should the dose/volume remain the same as for any WHO grade 2 tumor?